Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Cancers|January 11, 2024
Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent AdvancesMartina Canichella, Matteo Molica, Carla Mazzone, et al.
Diseases (Basel, Switzerland)|July 25, 2025
Therapeutic Implications of Menin Inhibitors in the Treatment of Acute Leukemia: A Critical ReviewMartina Canichella, Cristina Papayannidis, Carla Mazzone, et al.
Cancers|May 13, 2026
The Path Forward in MF: Small Molecules in the LimelightElisabetta Abruzzese, Malgorzata Monika Trawinska, Simona Bernardi, et al.
Cancers|August 14, 2025
Treatment-Free Remission in Ph+ ALL Without Allogeneic Stem Cell Transplantation: Current Evidence and Future DirectionsMartina Canichella, Malgorzata Monika Trawinska, Carla Mazzone, et al.
Cancers|June 24, 2022
CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AMLMatteo Molica, Salvatore Perrone, Carla Mazzone, et al.
Expert Review of Anticancer Therapy|July 5, 2018
Current and future therapeutic approaches for the treatment of follicular lymphomaAlessandro Pulsoni, Luca Vincenzo Cappelli, Laura Ballotta, et al.
Mediterranean Journal of Hematology and Infectious Diseases|September 19, 2019
Response to Interferon-Free Direct Antivirals (DAAS) Treatment in Hcv-Related Subcutaneous Marginal Zone B-Cell Lymphoma with Lipoma-Like Presentation: Report of Two CasesMaria Lucia De Luca, Laura Lombardi, Germana Tartaglia, et al.
Hematological Oncology|August 17, 2021
Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemiaMichela Ansuinelli, Irene Della Starza, Alessia Lauretti, et al.
European Journal of Haematology|June 14, 2018
Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?Roberto Latagliata, Massimo Breccia, Ida Carmosino, et al.
Leukemia & Lymphoma|July 13, 2019
Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocolRenato Bassan, Monica Fumagalli, Sabina Chiaretti, et al.
Pageof 3